Eterna Therapeutics Inc. announced the appointment of Matt Angel, Ph.D. as Chief Executive Officer (‘CEO') and President. Dr. Angel has served as Interim CEO and President of Eterna since May 2022 and will continue to serve on the Company's Board of Directors. Dr. Angel joined Eterna as Interim CEO and President in May 2022 and was appointed a member of the Board of Directors.

He is an experienced biotechnology entrepreneur and executive with deep experience in intellectual property protection and licensing, contract negotiation, including collaboration and licensing agreements, and has raised more than $150 million through grants, equity financings, and M&A. A pioneer in mRNA technology, Dr. Angel is a prolific inventor with more than 100 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies. In addition to his role at Eterna, Dr. Angel serves as Co-Founder, Chairman and CEO of Factor Bioscience Inc., and Co-Founder and Scientific Advisory Board Chair of Exacis Biotherapeutics. He previously served as Co-Founder and Chief Scientific Officer of Novellus Therapeutics, which was acquired by Eterna in 2021.

Dr. Angel received his B.S.E. from Princeton University and Ph.D. from the Massachusetts Institute of Technology.